Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

421 articles

Keyword: Skin cancerClear keyword
Nanomedicine (London, England)2026ReviewDrug Delivery

1. Evolving skin cancer therapeutics: molecular and genetic drivers, immunotherapy challenges, and advances in nanogel-based nanomedicine

Aafreen S, Abdur Rehman S, Parvez Barbhuiya T, Rizg Wy, Alghamdi Ma, Md S, Et Al.

Skin cancer is among the most common malignancies worldwide, with a rising global incidence. Cancer develops through complex molecular and genetic changes. Current treatments, such as surgery, chemotherapy, targeted therapy, radiation, and immunotherapy, offer hope. However, challenges like immune evasion, drug resistance, and systemic toxicities prevent long-term success. Nanotechnology-based delivery systems may offer a potential solution to these challenges.

Skin cancerimmunotherapynanogelstargeted therapytranslational research
Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.
Articles | Brilliant Blue Biosciences